
-
Arbutus Biopharma Corporation NasdaqGS:ABUS Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Location: 701 Veterans Circle, Warminster, PA, 18974, United States | Website: https://www.arbutusbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
536.4M
Cash
112.7M
Avg Qtr Burn
-14.74M
Short % of Float
8.44%
Insider Ownership
21.89%
Institutional Own.
59.32%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Imdusiran +NA therapy +IFN Details Hepatitis B | Phase 2a Update | |
AB-101 Details Hepatitis B | Phase 1 Data readout | |
AB-836 (capsid inhibitor) Details Hepatitis B | Failed Discontinued | |
Imdusiran +NA therapy + VTP-300 Details Hepatitis B | Failed Discontinued | |
Failed Discontinued | ||
AB-161 (Oral RNA destabilizer) Details Hepatitis B | Failed Discontinued |